Michael Spannagl Selected Research

Michael Spannagl Research Topics

Disease

23	Hemorrhage 03/2021 - 05/2002
14	Thrombosis (Thrombus) 02/2022 - 01/2004
10	Hemophilia A (Haemophilia) 07/2021 - 06/2005
5	Stroke (Strokes) 01/2020 - 08/2010
5	Thrombocytopenia (Thrombopenia) 12/2019 - 12/2007
5	Infections 12/2017 - 01/2004
4	Wounds and Injuries (Trauma) 03/2021 - 11/2012
4	Neoplasms (Cancer) 01/2021 - 10/2008
4	von Willebrand Diseases (von Willebrand's Disease) 11/2019 - 02/2010
4	Venous Thromboembolism 01/2013 - 12/2007
3	Atherosclerotic Plaque (Atheroma) 01/2021 - 03/2019
3	Atrial Fibrillation 01/2020 - 05/2012
3	Virus Diseases (Viral Diseases) 09/2014 - 12/2010
3	Thrombophilia 01/2011 - 09/2005
2	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 12/2019
2	Myocardial Infarction 01/2020 - 08/2010
2	Aortic Valve Stenosis (Aortic Stenosis) 04/2018 - 05/2011
2	Acute Coronary Syndrome 08/2017 - 02/2009
2	Hepatitis C 09/2013 - 10/2009
2	Venous Thrombosis (Deep-Vein Thrombosis) 09/2005 - 01/2005
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2020
1	Hemophilia B (Haemophilia B) 01/2020
1	Cardiovascular Diseases (Cardiovascular Disease) 04/2019
1	Heart Failure 04/2019
1	Vascular Diseases (Vascular Disease) 12/2017
1	Drug-Related Side Effects and Adverse Reactions 10/2017
1	Melanoma (Melanoma, Malignant) 01/2017
1	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2015
1	Hepatitis B 09/2014
1	Antithrombin III Deficiency 02/2014
1	Leukemia 01/2014
1	Inflammation (Inflammations) 02/2013
1	Acquired Protein S Deficiency 02/2012

Drug/Important Bio-Agent (IBA)

7	Factor VIII (Coagulation Factor VIII)IBA 03/2021 - 01/2005
5	von Willebrand FactorIBA 02/2022 - 01/2005
5	emicizumabIBA 07/2021 - 04/2019
5	AntigensIBA 12/2015 - 01/2005
4	Blood Coagulation Factors (Coagulation Factor)IBA 01/2020 - 06/2005
4	CollagenIBA 01/2020 - 01/2004
4	Heparin (Liquaemin)FDA LinkGeneric 12/2019 - 12/2007
4	AnticoagulantsIBA 09/2016 - 03/2009
3	Vitamin K FDA Link 01/2020 - 05/2012
3	CytokinesIBA 12/2017 - 10/2011
3	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 08/2017 - 07/2009
3	Thrombin FDA Link 05/2011 - 10/2008
3	fibrin fragment D (D-dimer)IBA 07/2008 - 01/2004
2	Agammaglobulinaemia Tyrosine KinaseIBA 01/2021 - 03/2019
2	PAR-1 ReceptorIBA 10/2020 - 01/2020
2	RivaroxabanIBA 10/2020 - 01/2020
2	Pharmaceutical PreparationsIBA 12/2019 - 09/2016
2	acalabrutinibIBA 12/2019 - 03/2019
2	ibrutinibIBA 12/2019 - 03/2019
2	SteroidsIBA 04/2019 - 04/2009
2	Prasugrel Hydrochloride FDA Link 08/2017 - 02/2013
2	TicagrelorIBA 08/2017 - 02/2013
2	Clopidogrel (Plavix)FDA Link 08/2017 - 02/2013
2	certoparin (certoparin sodium)IBA 01/2013 - 11/2012
2	Deamino Arginine Vasopressin (Desmopressin)FDA LinkGeneric 01/2012 - 05/2011
2	Fibrinogen (Factor I)FDA Link 12/2011 - 03/2010
2	Adenosine Diphosphate (ADP)IBA 05/2011 - 01/2004
1	remibrutinibIBA 01/2021
1	Factor Xa InhibitorsIBA 01/2020
1	Peptide Hydrolases (Proteases)FDA Link 01/2020
1	Factor IX (Coagulation Factor IX)FDA LinkGeneric 01/2020
1	Fc Receptors (Fc Receptor)IBA 12/2019
1	zanubrutinibIBA 12/2019
1	fenebrutinibIBA 12/2019
1	tirabrutinibIBA 12/2019
1	evobrutinibIBA 12/2019
1	platelet membrane glycoprotein VIIBA 03/2019
1	Toll-Like Receptor 3IBA 12/2017
1	Poly I-CIBA 12/2017
1	Protein CIBA 12/2017
1	Viral RNAIBA 12/2017
1	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 08/2017
1	Purinergic P2Y Receptor AntagonistsIBA 08/2017
1	Immune Checkpoint InhibitorsIBA 01/2017
1	IpilimumabIBA 01/2017
1	HLA Antigens (Human Leukocyte Antigens)IBA 12/2015
1	AutoantigensIBA 12/2015
1	Interleukin-17 (Interleukin 17)IBA 12/2015
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 12/2015
1	HLA-C Antigens (HLA-C)IBA 12/2015
1	AntibodiesIBA 07/2015
1	cancer procoagulantIBA 07/2015
1	InterferonsIBA 09/2014
1	Transcription Factors (Transcription Factor)IBA 09/2014
1	AntithrombinsIBA 02/2014
1	HLA-B Antigens (HLA-B)IBA 01/2014
1	EpitopesIBA 09/2013
1	HLA-A Antigens (HLA-A)IBA 09/2013
1	LipidsIBA 02/2013
1	argatroban (MPQA)FDA Link 04/2012
1	Protein SIBA 02/2012
1	Contraceptive Agents (Contraceptives)IBA 02/2012

Therapy/Procedure

8	Therapeutics 01/2020 - 06/2005
2	Stents 08/2013 - 02/2013
1	Cardiac Rehabilitation 04/2019
1	Secondary Prevention 08/2017
1	Drug-Eluting Stents 08/2013